Targets › CXCR4
16 programs from 15 companies in 20 trials: 8 Phase 2, 8 Phase 1, 3 Phase 3, 1 Phase 4; Oncology, Hematology, Infectious disease; next expected readout Dec 2026.
Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P61073)
Open in Phaseline: the race on CXCR4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Guangzhou Gloria Biosciences | Motixafortide (BL-8040) C-X-C chemokine receptor type 4 antagonist | CXCR4 | Phase 3 | Multiple Myeloma; Pancreatic Cancer; Acute Myeloid Leukemia; Sickle Cell Disease | May 2027 |
| X4 Pharmaceuticals | Mavorixafor C-X-C chemokine receptor type 4 antagonist | CXCR4 | Phase 3 | Neutropenia | Sep 2027 |
| BioLineRx | Motixafortide (BL-8040) C-X-C chemokine receptor type 4 antagonist | CXCR4 | Phase 3 | Multiple Myeloma | Sep 2029 |
| Koo Foundation Sun Yat-Sen Cancer Center | Ga-68-CXCR4 CXCR4-targeting radiopharmaceutical for PET/CT imaging | CXCR4 | Phase 2 | Indolent B-Cell Non-Hodgkin Lymphoma | Apr 2027 |
| Memorial Sloan Kettering Cancer Center | Plerixafor C-X-C chemokine receptor type 4 partial agonist | CXCR4 | Phase 2 | Diffuse Large B-cell Lymphoma (DLBCL) | Oct 2027 |
| Thomas Jefferson University | Plerixafor C-X-C chemokine receptor type 4 partial agonist | CXCR4 | Phase 2 | Multiple Myeloma | Dec 2027 |
| Nantes University Hospital | [68Ga]Ga-PentixaFor CXCR4-targeting radiopharmaceutical for PET imaging | CXCR4 | Phase 2 | Multiple Myeloma | Dec 2029 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Plerixafor C-X-C chemokine receptor type 4 partial agonist | CXCR4 | Phase 2 | Idiopathic CD4-Positive | Oct 2030 |
| IRCCS San Raffaele | Plerixafor C-X-C chemokine receptor type 4 partial agonist | CXCR4 | Phase 2 | Chronic Granulomatous Disease X-linked (X-CGD) | – |
| The First Affiliated Hospital of Soochow University | CXCR4-enabled CCR9 chimeric antigen receptor T-cell injection CAR-T cells engineered to express chimeric antigen receptors targeting CXCR4 and CCR9 | CXCR4, CCR9 | Phase 1 | Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma | Dec 2026 |
| Peking Union Medical College Hospital | 68Ga-Pentixafor CXCR4-targeted PET/CT imaging agent | CXCR4 | Phase 1 | Cushing s Syndrome | Feb 2027 |
| M.D. Anderson Cancer Center | Plerixafor C-X-C chemokine receptor type 4 partial agonist | CXCR4 | Phase 1 | RUNX1 Familial Platelet Disorder | Jun 2027 |
| City of Hope Medical Center | Plerixafor C-X-C chemokine receptor type 4 partial agonist | CXCR4 | Phase 1 | Sickle Cell Disease | Jul 2027 |
| National Cancer Institute (NCI) | Plerixafor C-X-C chemokine receptor type 4 partial agonist | CXCR4 | Phase 1 | HIV | Jul 2027 |
| Nantes University Hospital | [177Lu]Lu-PentixaTher CXCR4-targeting radioligand therapy (177Lu-based radiopharmaceutical) | CXCR4 | Phase 1 | Acute Leukemia | Oct 2027 |
| St. Jude Children's Research Hospital | Plerixafor C-X-C chemokine receptor type 4 partial agonist | CXCR4 | Phase 1 | Bone Marrow Failure Syndrome | Dec 2028 |
Multiple Myeloma (5) Sickle Cell Disease (2) Indolent B-Cell Non-Hodgkin Lymphoma (1) Pancreatic Cancer (1) Acute Myeloid Leukemia (1) Idiopathic CD4-Positive (1) Diffuse Large B-cell Lymphoma (DLBCL) (1) Acute Leukemia (1) Neutropenia (1) Chronic Granulomatous Disease X-linked (X-CGD) (1) RUNX1 Familial Platelet Disorder (1) HIV (1)
small molecule (10), mixed (4), protein or peptide (1), other (1)
Nantes University Hospital (2) Koo Foundation Sun Yat-Sen Cancer Center (1) Guangzhou Gloria Biosciences (1) BioLineRx (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) Memorial Sloan Kettering Cancer Center (1) X4 Pharmaceuticals (1) IRCCS San Raffaele (1) M.D. Anderson Cancer Center (1) National Cancer Institute (NCI) (1) City of Hope Medical Center (1) Thomas Jefferson University (1) The First Affiliated Hospital of Soochow University (1) St. Jude Children's Research Hospital (1) Peking Union Medical College Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.